1035975-95-1

Basic information

• Product Name: 2-{3-[4-(4-isopropoxy-phenoxy)-phenyl]-1-methyl-prop-2-ynyl}-isoindole-1,3-dione
• Synonyms: 2-{3-[4-(4-isopropoxy-phenoxy)-phenyl]-1-methyl-prop-2-ynyl}-isoindole-1,3-dione
• CAS NO: 1035975-95-1
• Molecular Weight: 425.484
• Mol File: 1035975-95-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-{3-[4-(4-isopropoxy-phenoxy)-phenyl]-1-methyl-prop-2-ynyl}-isoindole-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{3-[4-(4-isopropoxy-phenoxy)-phenyl]-1-methyl-prop-2-ynyl}-isoindole-1,3-dione(1035975-95-1)
• EPA Substance Registry System: 2-{3-[4-(4-isopropoxy-phenoxy)-phenyl]-1-methyl-prop-2-ynyl}-isoindole-1,3-dione(1035975-95-1)

Safety Data

• Hazardous Substances Data: 1035975-95-1(Hazardous Substances Data)

Upstream product

• 903886-79-3 4-(4-isopropoxyphenoxy)phenyl bromide 
• 14396-89-5 2-(1-methylprop-2-ynyl)-1H-isoindole-1,3(2H)-dione 
• 136918-14-4 phthalimide 
• 106-37-6 1.4-dibromobenzene 
• 7495-77-4 4-isopropoxyphenol 
• 123-31-9 hydroquinone 

Downstream Products

• 1035975-92-8 N-{(2Z)-3-[4-(4-isopropoxyphenoxy)phenyl]-1-methylprop-2-enyl}acetamide 

Relevant articles and documents

NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME

The present invention relates to compounds of formula (I): Pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic diseases or conditions are also provided.

Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy) thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors

A structurally novel acetyl-CoA carboxylase (ACC) inhibitor is identified from high-throughput screening. A preliminary structure-activity relationship study led to the discovery of potent dual ACC1/ACC2 and ACC2 selective inhibitors against human recombinant ACC1 and ACC2. Selective ACC2 inhibitors exhibited IC50 1000-fold selectivity against ACC1. (S)-Enantiomer 9p exhibited high ACC2 activity and lowered muscle malonyl-CoA dose-dependently in acute rodent studies, whereas (R)-enantiomer 9o was weak and had no effect on the malonyl-CoA level.